SHH3 Antibody

What is SSH3 protein and what cellular functions does it regulate?

SSH3 (also known as SSH3L or Protein phosphatase Slingshot homolog 3) is a protein phosphatase that plays a critical role in regulating actin filament dynamics. It functions primarily by dephosphorylating and activating the actin binding/depolymerizing factor cofilin, which subsequently binds to actin filaments and stimulates their disassembly . This mechanism is essential for cytoskeletal reorganization, cell motility, and various cellular processes dependent on actin dynamics.

The calculated molecular weight of SSH3 is approximately 73 kDa based on its 659 amino acid sequence, though it is typically observed at 90-95 kDa in experimental conditions, likely due to post-translational modifications .

What types of SSH3 antibodies are available and how should I choose between them?

Currently, there are multiple validated SSH3 antibodies available for research applications, including:

• Rabbit Polyclonal SSH3 antibody (e.g., ab76945) - Generated using synthetic peptides within human SSH3

• Mouse Monoclonal SSH3 antibody (e.g., 68583-1-Ig) - Generated using SSH3 fusion proteins

When selecting an SSH3 antibody, consider the following factors:

• Experimental application: Different antibodies are validated for specific applications such as Western blot (WB), immunohistochemistry (IHC-P), immunoprecipitation (IP), and immunofluorescence (IF)

• Species reactivity: Confirm the antibody has been validated for your target species (most are validated for human samples)

• Clonality: Polyclonal antibodies recognize multiple epitopes and may provide higher sensitivity, while monoclonal antibodies target a single epitope with greater specificity

• Validation data: Review available validation data for your specific application to ensure reliable performance

What are the optimal conditions for using SSH3 antibodies in Western blotting?

Western blotting is a common application for SSH3 antibodies, with specific methodological considerations:

For optimal results, include positive controls from validated cell lines and appropriate loading controls. The discrepancy between predicted and observed molecular weights is common for SSH3 and likely reflects post-translational modifications .

How can I optimize immunohistochemistry protocols for SSH3 detection in tissue samples?

For immunohistochemical detection of SSH3 in formalin-fixed, paraffin-embedded (FFPE) tissue sections:

• Section preparation: Standard FFPE protocols with 4-6 μm sections are suitable

• Antigen retrieval: Heat-induced epitope retrieval is typically required

• Antibody dilution: 1:200 (1μg/ml) for rabbit polyclonal antibody ab76945

• Detection system: DAB (3,3'-diaminobenzidine) detection provides good results

• Validated tissues: Human colon carcinoma tissue has been validated for SSH3 detection

Optimization may be required for different tissue types, and incorporation of appropriate positive and negative controls is essential for accurate interpretation.

What are the recommended protocols for immunoprecipitation of SSH3?

Immunoprecipitation of SSH3 can be performed using the following methodology:

• Antibody concentration: Use 3μg antibody per mg of lysate (for ab76945)

• Sample preparation: Total cell lysates from SSH3-expressing cells (e.g., HeLa cells)

• IP procedure: Standard IP protocols with protein A/G beads are suitable

• Detection: Western blot using 0.04 μg/mL antibody concentration for detection

• Loading control: Load approximately 20% of IP material per lane

• Expected results: IP should yield a band at approximately 90-95 kDa corresponding to SSH3

This approach allows isolation of SSH3 and its binding partners for downstream analysis of protein-protein interactions.

Why might I observe multiple bands or unexpected molecular weights when using SSH3 antibodies?

Multiple bands or unexpected molecular weights in SSH3 detection may result from:

• Post-translational modifications: Phosphorylation and other modifications may alter migration patterns

• Alternative splicing: Different SSH3 isoforms may be present in certain tissues or cell types

• Proteolytic degradation: Sample preparation without proper protease inhibitors may cause degradation

• Cross-reactivity: Potential cross-reactivity with related proteins (e.g., other SSH family members)

• Non-specific binding: Insufficient blocking or high antibody concentration

To address these issues:

• Include positive controls with known SSH3 expression

• Compare results across multiple SSH3 antibodies targeting different epitopes

• Optimize sample preparation with appropriate protease and phosphatase inhibitors

• Perform validation using genetic approaches (siRNA knockdown, CRISPR knockout)

How can I validate the specificity of SSH3 antibodies in my experimental system?

Rigorous validation of SSH3 antibodies should include:

• Positive controls: Use cell lines with confirmed SSH3 expression (e.g., HeLa, A431, A549)

• Negative controls:

  • Primary antibody omission

  • Isotype controls

  • Pre-absorption with immunizing peptide

• Genetic validation:

  • siRNA or shRNA knockdown of SSH3

  • CRISPR-Cas9 knockout of SSH3

• Multiple antibody approach: Compare results from different SSH3 antibodies targeting distinct epitopes

• Cross-species validation: Test antibody across species if conservation is high enough

This multi-faceted validation approach ensures reliable and reproducible results in SSH3 research.

How can phage display technology be utilized to develop custom SSH3 antibodies?

Phage display offers a powerful high-throughput approach for generating custom SSH3 antibodies:

• Antigen preparation: SSH3 can be expressed as a hexa-His-tagged GST-SSH3 fusion protein for use as an antigen in phage display selections

• Library selection:

  • High-diversity synthetic Fab-phage libraries (e.g., Library F with 3×10^10 unique members) can be used

  • Multiple rounds of selection with negative pre-adsorption against GST alone

  • Enrichment analysis using ELISA comparing target binding vs. control binding

• Clone analysis:

  • Screening 12-24 clones per selection by phage ELISA

  • Positive clones show >10-fold higher signal for target vs. control

  • Sequence analysis to identify unique Fab-phage clones

• Affinity maturation:

  • Further rounds of selection with increasing stringency

  • Targeted mutagenesis to improve binding properties

This approach has been successfully applied to generate antibodies against multiple SH3 domain-containing proteins with high specificity .

How can computational approaches improve the design and application of SSH3 antibodies?

In silico methods are increasingly valuable for antibody design and optimization:

• Structural modeling:

  • Antibody structure modeling using homology and ab initio approaches

  • Framework and CDR modeling using specialized algorithms like RosettaAntibody

  • Structure refinement to optimize VH/VL interfaces

• Antibody-antigen docking:

  • Prediction of antibody-SSH3 complexes using docking algorithms

  • Interface optimization through energy minimization

  • Epitope mapping to guide experimental validation

• Stability assessment:

  • Computational prediction of thermal stability

  • Identification of aggregation-prone regions

  • Design of stabilizing mutations

• Allosteric effects analysis:

  • Molecular dynamics simulations to investigate conformational changes upon binding

  • Mapping of allosteric networks within the antibody-antigen complex

These computational approaches can significantly enhance antibody engineering efforts, reducing the experimental burden and accelerating development.

How can SSH3 antibodies be applied to study SSH3's role in specific signaling pathways?

SSH3 antibodies enable detailed investigation of SSH3's role in signaling networks through:

• Phosphorylation-state analysis:

  • Detection of SSH3 phosphorylation status under different cellular conditions

  • Correlation with cofilin phosphorylation/dephosphorylation

  • Analysis of upstream regulatory events

• Protein-protein interaction studies:

  • Immunoprecipitation followed by mass spectrometry to identify binding partners

  • Co-immunoprecipitation to confirm specific interactions

  • Analysis of complex formation during cellular responses

• Spatial regulation:

  • Immunofluorescence to track SSH3 subcellular localization

  • Co-localization with actin structures and related proteins

  • Live-cell imaging using anti-SSH3 nanobodies

• Temporal dynamics:

  • Time-course experiments following stimulation

  • Correlation with cytoskeletal reorganization events

  • Integration with phosphoproteomic data

These approaches provide mechanistic insights into how SSH3 contributes to actin cytoskeleton regulation in various cellular contexts.

How do SSH3 antibodies compare with antibodies against other SSH family members?

SSH3 belongs to a family that includes SSH1 and SSH2, necessitating careful antibody selection for specificity:

When studying SSH3 specifically:

• Select antibodies raised against unique regions of SSH3

• Validate specificity against recombinant SSH1, SSH2, and SSH3

• Consider using antibodies against post-translational modifications unique to SSH3

• Perform careful controls in systems expressing multiple SSH family members

What considerations are important when using SSH3 antibodies in different model systems?

Application of SSH3 antibodies across model systems requires careful consideration:

• Species cross-reactivity:

  • Most validated SSH3 antibodies are tested on human samples

  • Cross-reactivity with other species must be empirically determined

  • Sequence alignment can predict potential cross-reactivity

• Expression levels:

  • Detection methods must be optimized based on endogenous expression levels

  • Signal amplification may be required in low-expressing systems

• Isoform expression:

  • Different model systems may express different SSH3 isoforms

  • Antibody epitope location relative to isoform differences is critical

• Tissue-specific considerations:

  • Background staining varies across tissues

  • Autofluorescence or endogenous peroxidase activity may interfere with detection

  • Fixation and processing methods may affect epitope accessibility

Pilot studies with appropriate positive and negative controls should be performed when extending SSH3 antibody use to new model systems.

How might emerging antibody technologies enhance SSH3 research?

Emerging technologies offer new possibilities for SSH3 antibody applications:

• Single-domain antibodies (nanobodies):

  • Smaller size enabling access to cryptic epitopes

  • Improved tissue penetration

  • Potential for intracellular expression

• Antibody fragments and alternative scaffolds:

  • Fab, scFv, and non-antibody scaffold proteins

  • Tailored properties for specific applications

  • Reduced immunogenicity in in vivo applications

• Site-specific conjugation:

  • Precisely controlled labeling for imaging applications

  • Maintained binding activity after modification

  • Consistent antibody-to-label ratio

• Bispecific formats:

  • Simultaneous targeting of SSH3 and interaction partners

  • Improved specificity through avidity effects

  • Novel functional assays based on proximity

These technologies will expand the research toolkit for studying SSH3 biology with improved spatial and temporal resolution.

What are the prospects for developing therapeutic antibodies targeting SSH3?

While the search results don't specifically address therapeutic applications, SSH3's role in cytoskeletal regulation suggests potential therapeutic relevance:

• Target validation:

  • Current research-grade antibodies provide tools for biological validation

  • Phenotypic consequences of SSH3 inhibition must be thoroughly characterized

• Therapeutic considerations:

  • Intracellular localization presents delivery challenges

  • Cell-penetrating antibody formats may be required

  • Target specificity versus other SSH family members is critical

• Potential disease applications:

  • Cancer metastasis (cytoskeletal regulation)

  • Inflammatory conditions (leukocyte migration)

  • Neurological disorders (neuronal plasticity)

• Development pipeline:

  • Humanization of existing antibodies

  • Optimization of pharmacokinetic properties

  • Function-blocking versus degradation-inducing mechanisms

The therapeutic potential of SSH3 antibodies remains an open research area requiring further investigation of SSH3's role in disease processes.